- $316.16m
- $86.95m
- $139.93m
- 73
- 48
- 13
- 41
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.13 | ||
| Price to Tang. Book | 1.13 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 2.13 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -12.7% | ||
| Return on Equity | -11.98% | ||
| Operating Margin | -24.85% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 14.68 | 22.59 | 49.01 | 89.08 | 139.93 | 136.47 | 151.12 | 128.61% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -86.83 | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
RxSight, Inc. is a commercial-stage medical technology company dedicated to providing customized vision to patients following cataract surgery. The Company's proprietary RxSight Light Adjustable Lens system (RxSight system) is commercially available premium cataract technology that enables doctors to customize and optimize visual acuity for patients after surgery. The RxSight system consists of its RxSight Light Adjustable Lens (LAL), the RxSight Light Delivery Device (LDD), and accessories. Its LAL is an intraocular lens (IOL) made of photosensitive material that changes shape in response to specific patterns of ultraviolet (UV) light generated by its LDD. In contrast, with the RxSight system, the surgeon implants the LAL during a standard cataract procedure, determines refractive error with patient input several weeks following surgery and then uses the LDD to modify the LAL with the precise visual correction needed to achieve the patient's desired vision outcomes.
Directors
- Ron Kurtz PRE
- Shelley Thunen CFO
- Ilya Goldshleger COO
- Matthew Haller CTO
- Eric Weinberg OTH
- Julie Andrews DRC (49)
- Tamara Fountain DRC (59)
- Shweta Maniar DRC (38)
- Robert Palmisano DRC (75)
- Robert Warner DRC
- Last Annual
- December 31st, 2024
- Last Interim
- March 31st, 2025
- Incorporated
- March 5th, 1997
- Public Since
- July 30th, 2021
- No. of Shareholders
- 110
- No. of Employees
- 498
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
NASDAQ Global Market- Shares in Issue
- 40,636,981
- Address
- 100 COLUMBIA STREET, SUITE 120, ALISO VIEJO, 92656
- Web
- https://www.rxsight.com/
- Phone
- +1 9495217822
- Auditors
- Ernst & Young LLP
Upcoming Events for RXST
Q3 2025 Rxsight Inc Earnings Release
Similar to RXST
908 Devices
NASDAQ Global Market
Alpha Teknova
NASDAQ Global Market
Anteris Technologies Global
NASDAQ Global Market
AtriCure
NASDAQ Global Market
Beta Bionics
NASDAQ Global Market
FAQ
What is the RxSight share price?
As of Today at 05:01 UTC, shares in RxSight are trading at $7.78. This share price information is delayed by 15 minutes.
How has the RxSight share price performed this year?
Shares in RxSight last closed at $7.78 and the price had moved by -83% over the past 365 days. In terms of relative price strength the RxSight share price has underperformed the S&P500 Index by -85.4% over the past year.
What are the analyst and broker recommendations for RxSight?
The overall consensus recommendation for RxSight is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the RxSight dividend yield?
RxSight does not currently pay a dividend.
Does RxSight pay a dividend?
RxSight does not currently pay a dividend.
When does RxSight next pay dividends?
RxSight does not currently pay a dividend.
How do I buy RxSight shares?
To buy shares in RxSight you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of RxSight?
As of the previous close price of $7.78, shares in RxSight had a market capitalisation of $316.16m.
Where are RxSight shares listed?
Here are the trading details for RxSight:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: RXST
What kind of share is RxSight?
Based on an overall assessment of its quality, value and momentum RxSight is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a RxSight share price forecast for 2025?
The analyst consensus target price for shares in RxSight is $11.63. That is 49.49% above the last closing price of $7.78.
Analysts covering RxSight currently have a consensus Earnings Per Share (EPS) forecast of -$1.09 for the next financial year.
Find out moreWhat is the trend in the RxSight share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like RxSight. Over the past six months, its share price has underperformed the S&P500 Index by -78.28%.
As of the last closing price of $7.78, shares in RxSight were trading -71.23% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the RxSight PE Ratio?
The RxSight PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $7.78.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of RxSight?
RxSight's management team is headed by:
- Ron Kurtz - PRE
- Shelley Thunen - CFO
- Ilya Goldshleger - COO
- Matthew Haller - CTO
- Eric Weinberg - OTH
- Julie Andrews - DRC
- Tamara Fountain - DRC
- Shweta Maniar - DRC
- Robert Palmisano - DRC
- Robert Warner - DRC